论文部分内容阅读
用长期植入物控制施给患者胰岛素,是一种治疗糖尿病的革新技术。多年来科学家早有这种设想。但至今,由于机体免疫系统的影响,许多实验均告失败。本文所介绍的新技术,是把活的、会产生胰岛素的细菌充入胶囊,注射到体内。这些胶囊具有“人工脏器”的功能,可以稳定的流量释放胰岛素。实验发现:以稳定流量胰岛素施给患者引起糖尿病并发症较常规注射为少。据美国医生报告:在动物体内植入能长期产生胰岛素的微胶囊已首次成功。本方法利用微胶囊来保护胰细胞,避免了排异
With long-term implant control administered to patients with insulin, is an innovative technology for the treatment of diabetes. Scientists have long had this idea for years. But so far, many experiments have failed because of the immune system. The new technology introduced in this article is to inject live, insulin-producing bacteria into the capsule and into the body. These capsules have the function of an “artificial organ” that releases insulin at a steady flow rate. Experiments found that: a steady flow of insulin administered to patients with diabetes complications than conventional injection is less. According to a report by a U.S. physician, it has been the first successful microcapsule to implant long-term insulin in animals. The method uses microcapsules to protect pancreatic cells and avoids rejection